Triazolopyridine Inhibitors of p38

Experimental Data Snapshot

  • Resolution: 2.30 Å
  • R-Value Free: 0.247 
  • R-Value Work: 0.193 
  • R-Value Observed: 0.196 

wwPDB Validation   3D Report Full Report

Ligand Structure Quality Assessment 

This is version 1.1 of the entry. See complete history


Design and Synthesis of Inhaled P38 Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease.

Millan, D.S.Bunnage, M.E.Burrows, J.L.Butcher, K.J.Dodd, P.G.Evans, T.J.Fairman, D.A.Hughes, S.J.Kilty, I.C.Lemaitre, A.Lewthwaite, R.A.Mahnke, A.Mathias, J.P.Philip, J.Smith, R.T.Stefaniak, M.H.Yeadon, M.Phillips, C.

(2011) J Med Chem 54: 7797

  • DOI: https://doi.org/10.1021/jm200677b
  • Primary Citation of Related Structures:  
    2YIS, 2YIW, 2YIX

  • PubMed Abstract: 

    This paper describes the identification and optimization of a novel series of DFG-out binding p38 inhibitors as inhaled agents for the treatment of chronic obstructive pulmonary disease. Structure based drug design and "inhalation by design" principles have been applied to the optimization of the lead series exemplied by compound 1a. Analogues have been designed to be potent and selective for p38, with an emphasis on slow enzyme dissociation kinetics to deliver prolonged lung p38 inhibition. Pharmacokinetic properties were tuned with high intrinsic clearance and low oral bioavailability in mind, to minimize systemic exposure and reduce systemically driven adverse events. High CYP mediated clearance and glucuronidation were targeted to achieve high intrinsic clearance coupled with multiple routes of clearance to minimize drug-drug interactions. Furthermore, pharmaceutical properties such as stability, crystallinity, and solubility were considered to ensure compatibility with a dry powder inhaler. 1ab (PF-03715455) was subsequently identified as a clinical candidate from this series with efficacy and safety profiles confirming its potential as an inhaled agent for the treatment of COPD.

  • Organizational Affiliation

    Worldwide Medicinal Chemistry, Pfizer Global Research and Development , Sandwich Laboratories, Ramsgate Road, Sandwich, Kent, CT13 9NJ, U.K. david.millan@gmail.com

Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
MITOGEN-ACTIVATED PROTEIN KINASE 14351Homo sapiensMutation(s): 0 
UniProt & NIH Common Fund Data Resources
Find proteins for Q16539 (Homo sapiens)
Explore Q16539 
Go to UniProtKB:  Q16539
PHAROS:  Q16539
GTEx:  ENSG00000112062 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ16539
Sequence Annotations
  • Reference Sequence
Small Molecules
Ligands 1 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
Query on YIX

Download Ideal Coordinates CCD File 
B [auth A]1-ethyl-3-(2-{[3-(1-methylethyl)[1,2,4]triazolo[4,3-a]pyridin-6-yl]sulfanyl}benzyl)urea
C19 H23 N5 O S
Binding Affinity Annotations 
IDSourceBinding Affinity
YIX Binding MOAD:  2YIX Kd: 3.3 (nM) from 1 assay(s)
PDBBind:  2YIX Kd: 3.3 (nM) from 1 assay(s)
BindingDB:  2YIX Kd: 3.3 (nM) from 1 assay(s)
IC50: 58 (nM) from 1 assay(s)
Experimental Data & Validation

Experimental Data

  • Resolution: 2.30 Å
  • R-Value Free: 0.247 
  • R-Value Work: 0.193 
  • R-Value Observed: 0.196 
  • Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 45.944α = 90
b = 86.523β = 90
c = 122.58γ = 90
Software Package:
Software NamePurpose

Structure Validation

View Full Validation Report

Ligand Structure Quality Assessment 

Entry History 

Revision History  (Full details and data files)

  • Version 1.0: 2011-11-30
    Type: Initial release
  • Version 1.1: 2024-05-08
    Changes: Data collection, Database references, Derived calculations, Other